Abstract: The present invention provides proteinaceous molecules to encode solutions to computational problems. In one aspect, a proteinaceous molecule is used as a representation of a combination of values for variables of a computational problem. In a second aspect, a library of proteinaceous molecules representing essentially all relevant solutions to at least one computational problem are used. The invention further provides a nucleic acid library encoding a library of proteinaceous molecules according to the invention. In another aspect, the invention includes a method for detecting a proteinaceous molecule representing a combination of values for variables of a computational problem comprising contacting a library of proteinaceous molecules of the invention, with a set of binding molecules designed for binding to proteinaceous molecules representing solutions.

Abstract: The present invention concerns novel C2,5?-disubstituted and N6,C2,5?-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value in the treatment and prophylaxis of diseases and disorders affected by adenosine receptor agonists.

Abstract: Novel C2,8-disubstituted adenosine derivatives disclosed herein have been found to be potent adenosine receptor agonists, in particular for the A2A receptor. The said compounds have biological activity against conditions such as hypertension, ischemic heart disease, ischemic brain disease, psychosis and wound healing. Further, the invention also discloses a process for the preparation of such compounds and pharmaceutical compositions comprising them.

Abstract: The present invention concerns novel C2,5?-disubstituted and N6?,C2,5?-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value in the treatment and prophylaxis of diseases and disorders affected by adenosine receptor agonists.

Abstract: The invention relates to a method of modulating plant growth or developmental processes in a plant or plant cell, more particularly, organogenesis and/or embryogenesis, through the provision of a plant protein which can act as a transcriptional regulator of the processes. The invention further provides a plant and propagating material thereof which contains, in its genome, a nucleotide sequence encoding a protein of the invention, the protein characterized in that it includes the amino acid sequence PRGRPPGSKNK (SEQ ID NO:2).

Abstract: The invention relates to industrial microbiology, in particular to fermentation technology and especially to fermentation methods for filamentous microorganisms, in particular, filamentous microorganisms such as actinomycetes. The present invention discloses a method for improving the production of a product of interest in a liquid culture of filamentous microorganisms comprising providing the filamentous microorganisms with an agent for altering the morphology of microstructures of the filamentous microorganisms. The invention also relates to a method for improving the production of a product of interest in a liquid culture of filamentous microorganisms comprising altering in the filamentous microorganisms the expression level or copy number of an endogenous agent for altering the morphology of microstructures of the filamentous microorganisms. The invention further provides multiple methods for obtaining a filamentous microorganism with altered, preferably enhanced, fragmentation characteristics.

Abstract: Provided are multiple methods resulting in a site-specific, marker-less integration of a sequence of interest. The methods are based on the following: The genomic presence in a cell (host cell) of a selectable or screenable gene X. As a result of a mutation, this gene X can be essentially sensitive or insensitive to a certain component or condition Z or, as a result of a mutation in gene X, the host cell is made dependent on the presence of a certain component or condition Z; a plasmid on which the desired insertion (or deletion) is present, further harboring a truncated gene X and a selectable marker (such as an antibiotic-resistance gene) to select or screen for the presence or absence of vector sequences in the host cell; positive selection of the final recombination step, avoiding complicated and time-consuming screening for the desired recombinants. Preferably, both recombination steps are positively selected.

Abstract: The present invention relates to novel nucleic acid and protein molecules and their use in neuroblastoma therapy and diagnosis.

Abstract: The present invention relates to a vascular prosthesis containing an active substance that has the capacity to stimulate the ingrowth of vascular cells, into the prosthesis. The present invention further relates to a method for the treatment of a vascular prosthesis, wherein the prosthesis is provided with an active substance capable of locally inducing the ingrowth of vascular cells, into the prosthesis material. Thus, the connection between vessel and prosthesis can be improved.

Abstract: The present invention concerns novel C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value in the treatment and prophylaxis of diseases and disorders affected by adenosine receptor agonists.

Abstract: The invention relates to peptidomimetic compounds with formula wherein Z═CH2 and Y═CH2, or Z═O and Y═O═O, which are novel analogs of glutathion and are inhibitors of glutathione S-transferase, in particular of GST P1-1. Such inhibition has beneficial effects in therapy against cancer. In particular compounds in which R3 is H, R4 is benzyl and R5 is phenyl are stable towards &ggr;GT activity and are selective for GST P1-1.

Abstract: The invention relates to methods for directing integration of a nucleic acid of interest towards homologous recombination and uses thereof. The present invention discloses factors involved in integration of a nucleic acid by illegitimate recombination which provides a method of directing integration of a nucleic acid of interest to a predetermined site, whereby the nucleic acid has a homology at or around the predetermined site, in a eukaryote with a preference for non-homologous recombination comprising steering an integration pathway towards homologous recombination. Furthermore, the invention provides a method of directing integration of a nucleic acid of interest to a subtelomeric and/or telomeric region in a eukaryote with a preference for non-homologous recombination.

Abstract: The invention relates to peptidomimetic compounds with formula 1

Abstract: Method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein C (APC). The method is directed at detecting one or more mutations at one or more of the cleavage and/or binding sites for APC of Factor V and/or Factor Va or at Factor VIII and/or Factor VIIIa at either nucleic acid or protein level or both.

Abstract: The invention provides transgenic nonhuman mammals producing phosphorylated lysosomal proteins in their milk, and methods of generating the same. Phosphorylation occurs at the 6' position of a mannose side chain residue. Also provided are methods of purifying lysosomal proteins from milk, and incorporating the proteins into pharmaceutical compositions for use in enzyme replacement therapy.

Abstract: Method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein C (APC). The method is directed at detecting one or more mutations at one or more of the cleavage and/or binding sites for APC of Factor V and/or Factor Va or at Factor VIII and/or Factor VIIIa at either nucleic acid or protein level or both.

Abstract: Method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein C (APC). The method is directed at detecting one or more mutations at one or more of the cleavage and/or binding sites for APC of Factor V and/or Factor Va or at Factor VIII and/or Factor VIIIa at either nucleic acid or protein level or both.

Abstract: Molecules complementary to nucleotide sequences encoding mutant ras proteins which contain a single-base mutation in the codon encoding amino acids at position 13, 12 or 61 have been produced. These molecules are useful in methods of detecting specific single-base mutations in altered ras genes and the specific cancers associated with such mutations.

Abstract: Molecules complementary to nucleotide sequences encoding mutant ras proteins which contain a single-base mutation in the codon encoding amino acids at position 13, 12 or 61 have been produced. These molecules are useful in methods of detecting specific single-base mutations in altered ras genes and the specific cancers associated with such mutations.

Abstract: Molecules complementary to nucleotide sequences encoding mutant ras protiens which contain a single-base mutation in the codon encoding amino acids at position 13, 12 or 61 have been produced. These molecules are useful in methods of detecting specific single-base mutations in altered ras genes and the specific cancers associated with such mutations.